trelagliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dipeptidyl aminopeptidase-IV inhibitors 5013 865759-25-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • TAK-472
  • trelagliptin
  • trelagliptin succinate
  • SYR-472
  • SYR111472
  • zafatek
Trelagliptin is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus.
  • Molecular weight: 357.39
  • Formula: C18H20FN5O2
  • CLOGP: 1.41
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 93.67
  • ALOGS: -3.22
  • ROTB: 3

Drug dosage:

None

ADMET properties:

None

Approvals:

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

External reference:

Pharmaceutical products:

None

trelagliptin